HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

NCT05886465 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
PROCEDURE: HAIC with FOLFOX

Sponsor

Sun Yat-sen University